



Original article

Effects of artificial liver support systems on nosocomial infections and mortality in non-transplanted liver failure patients

Yuan Li¹, Xiaoting Wang¹, Junkai Fan, Jiale Xie, Huimin Liu, Chunrong Ping, Zhijie Feng, Yan Wang*

Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive Diseases, Shijiazhuang, Hebei 050017, China

ARTICLE INFO

Article History:

Received 11 April 2025

Accepted 27 June 2025

Available online 9 September 2025

Keywords:

Liver failure

Artificial liver support systems

Nosocomial infection

Odds ratio

Hazard ratio

ABSTRACT

Introduction and Objectives: Artificial liver support systems (ALSS) offer a technical solution for patients with liver failure (LF), serving as a bridge to recovery or transplantation. However, the number of LF patients eligible for transplants is limited. This study investigates the incidence of nosocomial infections and survival outcomes in LF patients treated with ALSS who do not undergo liver transplantation.

Patients and Methods: A retrospective cohort study was conducted on LF patients receiving standard medical care (SMC) with ALSS versus those treated only with SMC. General and laboratory data were collected from all LF patients. A logistic regression model was used to assess the risk of nosocomial infections associated with ALSS use, while a Cox proportional hazards model was used to evaluate mortality risk in LF patients undergoing ALSS treatment. Survival times for both groups were calculated using Kaplan–Meier analysis.

Results: A total of 306 LF patients were analyzed, comprising 200 males (65.4%) and 106 females (34.6%), with an average age of 49.9 years (95% CI = 48.2–51.6). Multivariate logistic regression analysis showed that ALSS was not linked to the risk of nosocomial infections (odds ratio = 1.189, 95%CI=0.442–3.202, $p=0.732$). However, hazard ratio (HR) results indicated that ALSS is a protective factor for survival in LF patients (HR=0.533, 95%CI=0.374–0.760, $p=0.001$), supported by Kaplan–Meier curve analysis demonstrating prolonged survival time in the ALSS group among LF patients.

Conclusions: ALSS is not an independent risk factor for nosocomial infections and could effectively prolong the lifespan of LF patients without liver transplantation. Further intervention studies are needed to validate these findings.

© 2025 Published by Elsevier España, S.L.U. on behalf of Fundación Clínica Médica Sur, A.C. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

1. Introduction

Liver failure (LF) is a complex syndrome caused by various factors, leading to significant impairment of the liver's synthetic, detoxification, metabolic, and biotransformation functions. It can progress to multi-organ failure and result in death[1,2]. The global prevalence and mortality rates of LF are high and have remained stable over time[3,4]. Specifically, the mortality rate for acute LF is 29%, while it

can reach up to 48% for acute-on-chronic LF[5]. LF incurs substantial healthcare costs and poses a considerable burden on healthcare systems worldwide[6,7].

Currently, primary treatments for LF include standard medical care (SMC), artificial liver support systems (ALSS), and liver transplantation[8–10]. The goal of managing LF patients is to maintain or restore vital organ functions while preventing multi-organ failure. In this regard, ALSS is valuable as it provides critical time for spontaneous liver regeneration or facilitates emergency transplantation[11–13]. However, being an invasive treatment, ALSS carries risks, with nosocomial infection being the most common and serious complication[14,15]. The incidence of nosocomial infections in ALSS can reach 40.0%, often leading to poor outcomes[16]. Nearly one-third of patients experienced electrolyte disturbances and renal impairment, resulting in prolonged hospitalization; 12% required intensive care unit (ICU) admission. Additionally, these infections may lead to multiple organ failures, reducing chances for transplantation and increasing mortality rates[17,18]. Therefore, evaluating the uncertain

Abbreviations: ALSS, Artificial liver support systems; BMI, body mass index; CI, Confidence interval; HR, Hazard ratio; ICU, intensive care unit; INR, International normalized ratio; LF, Liver failure; MSCs, Mesenchymal stem cells; OR, Odds ratio; RCT, Randomized controlled trial; SMC, Standard medical care

* Corresponding author.

E-mail addresses: lyjyogo@163.com (Y. Li), 2579018216@qq.com (X. Wang), 1176911254@qq.com (J. Fan), 18713800336@163.com (J. Xie), lhm1119_2022@qq.com (H. Liu), 504647901@qq.com (C. Ping), 26300056@hebm.edu.cn (Z. Feng), wangyan_2006@aliyun.com (Y. Wang).

¹ Co-first authors: These authors contributed equally to this work and should be considered co-first authors.

<https://doi.org/10.1016/j.aohp.2025.102113>

1665-2681/© 2025 Published by Elsevier España, S.L.U. on behalf of Fundación Clínica Médica Sur, A.C. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

relationship between ALSS use and infections is crucial at this time. Although the efficacy of utilizing ALSS among LF patients has been extensively explored in previous studies, these randomized controlled trials (RCTs) were characterized by a limited number of LF cases and short-term follow-up periods[19]. This highlights the urgent need for longer follow-up periods among larger cohorts to adequately assess the impact of ALSS on the overall survival of LF patients.

Therefore, this study aimed to evaluate the relationship between the utilization of ALSS and the incidence risk of nosocomial infections, as well as the associated mortality risk in patients with LF.

2. Patients and Methods

2.1. Study design

This cohort study enrolled LF patients aged 18 years and older who received treatment at the Department of Gastroenterology, Second Hospital of Hebei Medical University, between June 2018 and August 2023. Comprehensive general and laboratory data were collected from all patients. This study received approval from the Research Ethics Committee of the participating hospital (Approval Letter No. 2023-R493). All patients provided informed consent to participate in this study. Additionally, informed consent was obtained from the family members of the patients prior to the initiation of ALSS.

2.2. Definition of LF patients

The diagnostic criteria for LF were in accordance with the 2018 guidelines for the diagnosis and treatment of LF[20]. Exclusion criteria included: (1) patients with incomplete primary clinical data; (2) individuals diagnosed with primary liver cancer or tumors located elsewhere; (3) patients with LF who presented infections upon admission or had pre-existing infections prior to undergoing ALSS treatment. Four patterns of LF patients (acute LF, sub-acute LF, acute-on-chronic LF, and chronic LF) were identified in this study based on the following diagnostic criteria[11]. Acute LF is characterized by rapid hepatic function decline within 2 weeks, evident bleeding tendency, plasma prothrombin activity $\leq 40\%$ (or international normalized ratio [INR] ≥ 1.5), and hepatic encephalopathy in patients without prior liver failure. Sub-acute LF occurs with a relatively urgent onset (2–26 weeks), serum total bilirubin >10 times the upper limit of normal or an increase of $17.1 \mu\text{mol/L}$ per day, obvious bleeding tendency, and prothrombin activity $\leq 40\%$ (or INR ≥ 1.5). Acute-on-chronic LF presents as short-term acute or sub-acute decompensated liver function on the background of chronic liver disease, with serum total bilirubin $>10 \times \text{ULN}$ or increasing more than $17.1 \mu\text{mol/L}$ daily, bleeding tendency, prothrombin activity $\leq 40\%$ (or INR ≥ 1.5), and decompensated cirrhosis with ascites. Chronic LF involves progressive deterioration and decompensation of liver function due to cirrhosis, marked increases in serum total bilirubin, significant decreases in albumin, evident bleeding tendency, prothrombin activity $\leq 40\%$ (or INR ≥ 1.5), ascites, portal hypertension, or hepatic encephalopathy.

2.3. Definition of SMC and ALSS groups

The patients in the SMC group received only standard medical treatment, whereas those in the ALSS group were administered a combination of SMC and ALSS. The ALSS comprised several modalities, including plasma exchange, plasma diafiltration, hemodiafiltration, hemoperfusion, and the double plasma molecular adsorption system.

2.4. Definition of primary and secondary outcomes

Nosocomial infection in LF patients is the primary outcome, defined as an infection occurring 48 hours after hospitalization[21]. This study identified six types of infections: pulmonary infection, urinary system infection, spontaneous bacterial peritonitis, upper respiratory tract infection, acute biliary tract infection, and bloodstream infection. Pulmonary infection was defined by either a positive sputum culture or clinical manifestations such as fever, cough, sputum production, along with imaging changes. Chest imaging (chest X-ray or CT) revealed new or progressive infiltration/consolidation accompanied by one or more of the following clinical symptoms: fever, expectoration, cough, and dyspnea, and peripheral white blood cell count exceeding $10 \times 10^9/\text{L}$ or falling below $4 \times 10^9/\text{L}$. Urinary system infections were diagnosed based on positive urine cultures; additional indicators included lower back pain and fever associated with upper urinary tract infections alongside renal percussion pain and increased urine white blood cells; they are alternatively characterized by frequent urination, urgency, and dysuria indicative of lower urinary tract infections also showing elevated urinary white blood cells. Spontaneous bacterial peritonitis was diagnosed based on clinical signs consistent with peritonitis; ascitic neutrophil counts $\geq 25 \times 10^6/\text{L}$; exclusion of surgical secondary peritonitis; and either positive or negative ascitic fluid cultures. Upper respiratory tract infections are characterized as common viral infections affecting the nasal passages, pharynx, and upper airways, manifesting symptoms such as rhinorrhea (runny nose), nasal congestion, cough sneezing episodes sore throat, and headaches. Acute biliary tract infections primarily encompass acute cholecystitis and acute cholangitis, confirmed through symptomatology, inflammation, and imaging findings. Bloodstream infections include sepsis as well as catheter-related complications, where two infections are diagnosed via blood culture results combined with bone marrow analysis.

The secondary outcome of interest in this study was all-cause mortality. Dates of death were obtained either from officially issued death certificates or through interviews with close family members or village doctors when available. The duration of follow-up was defined as the interval between the date of the interview conducted in 2018 and the occurrence of outcomes, or until 2023. In instances where a participant missed a follow-up visit, their survival time was calculated as the period between their interview date in 2018 and the date of the missed visit.

2.5. Definition of covariates

General data included age, sex, length of hospital stays, height, weight, body mass index (BMI), smoking status, drinking habits, history of disease (hypertension and diabetes), and etiology of LF. Laboratory data included C-reactive protein, procalcitonin, white blood cell count, neutrophil count, monocyte count, lymphocyte count, hemoglobin level, platelet count, INR, prothrombin activity and time, cholinesterase level, total bilirubin level, alanine aminotransferase, aspartate aminotransferase, albumin level, creatinine level, sodium ion concentration, potassium ion concentration, and blood ammonia levels.

Age was divided into two groups: ≥ 50 and <50 years. Hospital stays were categorized as short or long based on the median duration of 16 days. BMI was classified as obesity ($\geq 28.0 \text{ kg}^2/\text{m}$) and non-obesity ($<28.0 \text{ kg}^2/\text{m}$). Smoking and drinking statuses were assessed by asking participants if they currently smoke or drink. A history of diseases was determined by the question, "Did you suffer from hypertension or diabetes?" A response of 'yes' was recorded as yes; otherwise, it was noted as no. The etiology of LF was categorized into virus-induced LF and other causes. Laboratory data were classified as abnormal or normal based on clinical cutoff values.

2.6. Statistical analysis

The descriptive statistics of baseline characteristics were presented in accordance with the risk status for nosocomial infection and mortality. Continuous variables are reported as means accompanied by a 95% confidence interval (CI). Categorical variables were displayed as frequencies and percentages. One-way ANOVA was utilized to compare differences among continuous variables, while Chi-square tests were employed for categorical variables.

Logistic regression and Cox proportional hazards models were used to calculate odds ratios (ORs) with 95% CIs, as well as hazard ratios (HRs) with their 95% CIs. The backward stepwise regression method identified significant covariates for both univariable and multivariable analyses, which were included in the final models. We also conducted subgroup analyses and examined interaction effects, revealing an association between ALSS and mortality in LF patients based on demographic factors. Missing data in patients with less than 10% incomplete records were addressed using multiple imputation techniques. The significance level was set at $\alpha=0.05$, with $p<0.05$ indicating statistical significance. All analyses were conducted using R software version 4.3.1, with statistical significance determined by a two-tailed p-value of less than 0.05.

3. Results

3.1. Descriptive analyses

In this study, 421 LF patients aged ≥ 18 years were enrolled. Due to missing data, 115 patients were excluded from the analysis. Ultimately, our analysis included 306 LF patients with an average baseline age of 49.9 years (95% CI: 46.2–53.6); among them, there were 200 (65.4%) males and 106 (34.6%) females. A total of 131 patients with LF received a combination of SMC and ALSS treatment. The majority of these patients (97.7%) underwent either plasma exchange or a combination of plasma exchange and double plasma molecular adsorption. Additionally, a limited number of patients (2.29%) presenting with renal failure or hepatic encephalopathy were treated using plasma diafiltration. In contrast, there were 175 LF patients in the SMC group who received only standard medical treatment.

3.2. Association of ALSS use and nosocomial infection

The ALSS group reported 66 cases of nosocomial infections, while the SMC group documented 69 cases of nosocomial infections. No significant differences were observed between the two groups with respect to covariates, with the exception of hospital stays, C-reactive protein levels, neutrophil counts, hemoglobin levels, platelet counts, INR values, and cholinesterase levels. [Table 1](#) presents the characteristics of study participants based on their infectious status during hospitalization.

The relationship between ALSS and the risk of nosocomial infection was assessed using logistic regression models adjusted for covariates ([Table 2](#)). Patients with LF in the ALSS group demonstrated a non-significant association with the risk of nosocomial infection (OR=1.189, 95% CI=0.442–3.202, $p=0.732$) when compared to those in SMC group. Similar associations were observed across other covariates; however, patients with LF who smoked and drank exhibited a significantly increased risk of nosocomial infection compared to non-smokers (OR=2.100, 95% CI=1.417–2.897, $p=0.007$) and non-drinkers (OR=1.567, 95% CI=1.021–2.778, $p=0.012$), respectively.

3.3. Association of ALSS use and mortality

Over the entire follow-up period, we identified 150 deaths in the cohort: specifically, 55 deaths in the ALSS group and 95 in the SMC

Table 1

Demographic and clinical characteristics of the 306 patients with LF, categorized by their infectious status during hospitalization.

Characteristics	Nosocomial infection	Non-nosocomial infection	P-value
Total number (%)	135(44.1)	171(55.9)	
Sex (male, %)	95(47.5)	105(52.5)	0.102
Age (years)	50.0(47.6, 52.5)	49.8(47.8, 51.9)	0.898
Hospital stays (days)	20.1(18.0, 22.2)	16.7(15.2, 18.3)	0.010
Height (cm)	167.7 (166.3, 169.0)	167.6 (166.5, 168.7)	0.885
Weight (kg)	70.1 (67.6, 72.7)	69.6 (67.8, 71.4)	0.730
BMI	24.8 (24.0, 25.6)	24.7 (24.2, 25.2)	0.727
Smoke status (yes, %)	53(44.6)	44(45.4)	0.120
Drink status (yes, %)	57(46.3)	66(53.7)	0.521
Hypertension (yes, %)	20(38.5)	32(61.5)	0.367
Diabetes (yes, %)	9(28.1)	23(71.9)	0.054
Virus-induced LF (yes, %)	81(44.0)	103(56.0)	0.967
ALSS (yes, %)	66(50.4)	65(49.6)	0.170
C-reactive protein (mg/L)	22.8 (17.3, 28.4)	16.2(12.6, 19.8)	0.034
Procalcitonin (ng/ml)	1.32 (0.90, 1.74)	0.83 (0.59, 1.08)	0.055
White cell count (10^9 L)	8.39 (7.05, 9.73)	7.00 (6.29, 7.72)	0.067
Neutrophils (10^9 L)	6.27 (5.06, 7.47)	4.61 (4.02, 5.20)	0.013
Monocytes (10^9 L)	0.75 (0.65, 0.84)	0.92 (0.68, 1.15)	0.197
Lymphocytes (10^9 L)	1.35 (0.96, 1.74)	1.51 (1.27, 1.75)	0.483
Hemoglobin (g/L)	116.4 (112.0, 120.9)	123.2 (117.6, 128.8)	0.045
Platelet (10^9 L)	108.2 (93.2, 123.3)	138.2 (125.3, 151.1)	0.002
International normalized ratio (INR)	2.45 (2.20, 2.71)	2.12 (1.97, 2.26)	0.022
Prothrombin activity	34.6 (31.1, 38.3)	40.2 (36.2, 44.2)	0.052
Prothrombin time (s)	27.6 (24.2, 30.9)	23.9 (21.9, 25.9)	0.073
Cholinesterase (U/L)	3026.4 (2764.6, 3288.2)	3703.0 (3429.0, 3977.0)	0.003
Total bilirubin (μ mol/L)	371.1 (340.4, 401.7)	353.1 (325.7, 380.5)	0.295
Aspartate aminotransferase (U/L)	347.1 (250.3, 444.0)	499.7 (402.5, 597.0)	0.050
Alanine aminotransferase (U/L)	348.5 (241.0, 456.0)	490.8(340.6, 641.0)	0.183
Albumin (g/L)	28.9 (27.9, 29.8)	31.5 (30.6, 32.4)	0.106
Creatinine (μ mol/L)	111.2 (82.1, 140.4)	83.7 (70.8, 96.7)	0.143
Potassium (mmol/L)	3.91 (3.76, 4.06)	4.06 (3.90, 4.21)	0.414
Sodium (mmol/L)	134.3 (132.9, 135.6)	135.1 (133.8, 136.4)	0.189
Blood ammonia (μ mol/L)	80.4 (71.8, 89.0)	77.8 (70.1, 85.4)	0.776

LF, liver failure; BMI, body mass index; ALSS, Artificial Liver Support Systems.

group were observed. [Table 3](#) presents the characteristics of study participants according to follow-up outcomes.

[Table 4](#) presents the association between ALSS and the risk of mortality, which was assessed using Cox proportional hazard models adjusted for covariates. Patients with LF in the ALSS group illustrated a lower risk of mortality than that in patients in the SMC group (HR=0.533, 95% CI=0.374–0.760, $p=0.001$). The Kaplan-Meier analysis yielded comparable results, as illustrated in [Fig. 1](#). However, nosocomial infection was not a significant risk factor for mortality (HR=1.089, 95% CI=0.775–1.530, $p=0.645$). In analyses of the procalcitonin test, we found that LF patients with high levels of procalcitonin had a higher risk of mortality than that in individuals with normal levels (HR=17.35, 95% CI=5.201–83.55, $p<0.001$).

In the subgroup analyses, a significant relationship between ALSS and a lower risk of mortality was found in most subgroups. The interaction effect analyses of ALSS and demographic factors showed no significant association ([Table 5](#)).

Table 2

Univariate and multivariate analyses demonstrating the association between demographic factors, clinical characteristics, and nosocomial infection in patients with LF.

Characteristics	Univariate OR(95%CI)	p-value	Multivariate OR(95%CI)	p-value
Sex				
Male vs. Female	1.493(0.923-2.415)	0.102	1.310(0.506-3.390)	0.578
Age group (years)				
≥50 vs. <50	0.938(0.596-1.475)	0.781	0.933(0.518-1.487)	0.755
Hospital stays				
Long vs. short	1.461(0.943-2.263)	0.090		
BMI				
Non-obesity vs. Obesity	0.834(0.450-1.546)	0.564		
Smoke status				
Yes vs. No	2.343(1.246-4.405)	0.008	2.100(1.417-2.897)	0.007
Drink status				
Yes vs. No	1.375(1.053-2.510)	0.030	1.567(1.021-2.778)	0.012
Hypertension				
Yes vs. No	1.347(0.714-2.540)	0.358	1.077(0.414-2.805)	0.879
Diabetes				
Yes vs. No	0.488(0.215-1.110)	0.087	0.507(0.207-2.187)	0.199
Virus-induced LF				
Yes vs. No	0.990(0.625-1.570)	0.967		
ALSS				
Yes vs. No	1.560(0.987-2.465)	0.001	1.189(0.442-3.202)	0.732
C-reactive protein				
Normal vs. Abnormal	1.338(0.698-2.567)	0.380		
Procalcitonin				
Normal vs. Abnormal	1.078(0.066-17.534)	0.958	1.546(0.470-5.093)	0.473
White cell count				
Normal vs. Abnormal	0.601(0.284-1.274)	0.184		
Neutrophils				
Normal vs. Abnormal	1.702(0.879-3.296)	0.115	1.419(0.522-3.858)	0.493
Monocytes				
Normal vs. Abnormal	0.909(0.345-2.397)	0.848		
Lymphocytes				
Normal vs. Abnormal	1.064(0.592-1.912)	0.836		
Hemoglobin				
Normal vs. Abnormal	1.130(0.642-1.992)	0.671	1.315(0.625-2.770)	0.470
Platelet				
Normal vs. Abnormal	1.652(0.807-3.379)	0.169		
International normalized ratio (INR)				
Normal vs. Abnormal	1.956(0.349-10.949)	0.445		
Prothrombin activity				
Normal vs. Abnormal	1.154(0.522-2.549)	0.723		
Prothrombin time				
Normal vs. Abnormal	1.557(0.505-4.801)	0.441		
Cholinesterase				
Normal vs. Abnormal	1.412(0.513-3.883)	0.504	1.842(0.726-4.675)	0.199
Total bilirubin				
Normal vs. Abnormal	1.091(0.567-2.099)	0.794		
Aspartate aminotransferase				
Normal vs. Abnormal	1.023(0.141-7.421)	0.610		
Alanine aminotransferase				
Normal vs. Abnormal	0.726(0.320-1.646)	0.443		
Albumin				
Normal vs. Abnormal	1.178(0.499-2.777)	0.709		
Creatinine				
Normal vs. Abnormal	1.571(0.502-4.923)	0.438		
Potassium				
Normal vs. Abnormal	1.065(0.565-2.010)	0.845	1.076(0.646-1.794)	0.777
Sodium				
Normal vs. Abnormal	0.672(0.254-1.773)	0.422		
Blood ammonia				
Normal vs. Abnormal	2.071(0.938-4.574)	0.072		

LF, liver failure; OR, odds ratio; CI: confidential interval; BMI, body mass index; ALSS, Artificial Liver Support Systems.

4. Discussion

This study indicated that ALSS is not an independent risk factor for nosocomial infections. The application of ALSS has the potential to significantly extend the lifespan of patients with LF. Moreover, no interaction was observed between ALSS and nosocomial infection concerning the mortality rates of LF patients.

Although nosocomial infection is one of the most frequently discussed issues in the treatment of ALSS, most previous studies focusing on the epidemiology of nosocomial infections in patients with LF have identified disease severity, age, and underlying conditions, as well as total bilirubin and albumin levels as primary risk factors[22–24]. Elevated total bilirubin levels, transfusion of blood products, and a higher number of invasive procedures were independent risk factors for

Table 3

Demographic and clinical characteristics of the 306 patients with LF, categorized by follow-up outcomes.

Characteristics	Survival group	Death group	P-value
Total number (%)	156(51.0)	150(49.0)	
Sex (male, %)	112(56.0)	88(44.0)	0.016
Age (years)	50.0(48.2-51.8)	49.6(46.2-53.1)	0.848
Hospital stays (days)	17.8(16.3-19.2)	19.0(16.5-21.4)	0.437
Height (cm)	167.6(166.6-168.6)	167.7(165.9-169.5)	0.890
Weight (kg)	69.7(68.0-71.4)	70.3(67.0-73.5)	0.758
BMI	24.7(24.2-25.2)	24.8(23.9-25.7)	0.805
Smoke status (yes, %)	56(57.7)	41(42.3)	0.108
Drink status (yes, %)	65(52.8)	58(47.2)	0.593
Hypertension (yes, %)	25(48.1)	27(51.9)	0.646
Diabetes (yes, %)	13(40.6)	19(59.4)	0.216
Virus-induced LF (yes, %)	96(52.2)	88(47.8)	0.608
ALSS (yes, %)	76(58.0)	55(42.0)	0.033
C-reactive protein (mg/L)	21.4(16.6-26.1)	16.7(12.3-21.1)	0.130
Procalcitonin (ng/ml)	1.23(0.87-1.59)	0.85(0.56-1.13)	0.148
White cell count ($10^9/L$)	7.68(6.63-8.73)	8.65(7.12-10.1)	0.240
Neutrophils ($10^9/L$)	5.54(4.58-6.50)	6.03(4.70-7.37)	0.441
Monocytes ($10^9/L$)	0.81(0.64-0.98)	0.87(0.68-1.06)	0.661
Lymphocytes ($10^9/L$)	1.37(1.09-1.64)	1.56(1.17-1.94)	0.432
Hemoglobin (g/L)	118.2(113.2-123.2)	119.6(114.1-125.3)	0.725
Platelet ($10^9/L$)	122.8(109.8-135.8)	119.6(100.3-138.9)	0.508
International normalized ratio (INR)	2.14(1.97-2.31)	2.59(2.27-2.91)	0.002
Prothrombin activity	40.3(36.6-44.1)	33.0(29.4-36.6)	0.003
Prothrombin time (s)	23.6(21.7-25.5)	29.0(25.1-32.9)	0.002
Cholinesterase (U/L)	3231.0(2990.1-3471.8)	3554.7(3226.2-3883.2)	0.119
Total bilirubin ($\mu\text{mol/L}$)	343.7(320.5-366.9)	390.0(352.8-427.2)	0.016
Aspartate aminotransferase (U/L)	449.1(352.5-545.6)	382.7(287.1-478.2)	0.376
Alanine aminotransferase (U/L)	487.1(346.3-627.8)	316.3(228.2-404.4)	0.163
Albumin (g/L)	30.3(29.3-31.2)	30.1(29.1-31.1)	0.702
Creatinine ($\mu\text{mol/L}$)	88.8(77.7-99.8)	111.0(74.0-148.0)	0.267
Potassium (mmol/L)	3.97(3.84-4.09)	4.00(3.81-4.20)	0.979
Sodium (mmol/L)	134.3(133.1-135.5)	135.3(133.8-136.8)	0.503
Blood ammonia ($\mu\text{mol/L}$)	75.9(69.3-82.6)	83.9(73.6-94.2)	0.185

LF, liver failure; BMI, body mass index; ALSS, Artificial Liver Support Systems.

nosocomial infection in patients undergoing ALSS treatment[14]. However, our study found that the use of ALSS may not be an independent factor associated with nosocomial infections in LF patients. Furthermore, a recent large RCT meta-analysis demonstrated that extracorporeal liver support/ALSS was not significantly linked to nosocomial infections (RR=1.92; 95% CI=0.11-33.44)[19]. Therefore, reconsidering the relationship between the utilization of ALSS and nosocomial infections in patients with LF in future research is essential.

Additionally, we identified smoking as an independent risk factor for nosocomial infection among LF patients. Cigarette smoking predisposes individuals to pulmonary infection. Hospitalized patients with a history of smoking are more prone to developing hospital-acquired infections [25,26]. Our findings further corroborated this association by confirming smoking as a significant risk factor for nosocomial infection. This condition may be attributed to cigarette smoke, which induces the generation of an inflammatory phenotype in mesenchymal stem cells (MSCs). This alteration reduced their

immunosuppressive properties and inhibited the capacity of MSCs to suppress inflammatory innate immune cells in the liver. Furthermore, it inhibited the production of inflammatory Th1 and Th17 lymphocytes, reducing the body's ability to fight infections. This led to an increased vulnerability to infections among individuals[27]. Our analyses also indicated that alcohol consumption is a significant contributor to the incidence of nosocomial infections[28]. Similar findings were noted in previous studies, where alcohol consumption was significantly associated with complications and adverse outcomes in LF patients[29,30]. Therefore, LF patients who engage in smoking and drinking habits should be monitored more closely due to their elevated risk of developing nosocomial infections.

The global prevalence and mortality rates associated with LF are notably high, while the accessibility of liver transplantation remains low for the majority of patients[31,32]. Extracorporeal liver support/ALSS has been recommended as an effective method for prolonging the lives of LF patients and serving as a bridge to liver transplantation [11]. The available evidence indicates that approximately 37% of patients listed for emergency liver transplantation demonstrate recovery following treatment with ALSS, while 50% unfortunately succumb while awaiting an organ[33]. A meta-analysis involving 25 RCTs, which included a total of 1,796 LF patients, reported that the use of extracorporeal liver support/ALSS was associated with a reduction in mortality (RR=0.84; 95%CI=0.74-0.96) among patients suffering from acute LF or acute-on-chronic LF[19]. Similar results were observed across all subgroups, except for those with smoking and diabetes-related LF. The toxic components of cigarette smoke enter the bloodstream through the lungs and affect various organs—including the lungs, liver, kidneys, heart, gut, blood vessels, and brain—thereby impairing their function[34]. Cigarette smoke induced oxidative stress and inflammation while triggering harmful immune responses in different tissues. It plays a significant role in the progression of bronchitis, emphysema, gastroenteritis, hepatitis, and non-alcoholic fatty liver disease; prolonged exposure to cigarette smoke notably increases the risk of lung, liver, and colon cancers, ultimately leading to mortality[35]. Available evidence suggests that diabetes may lead to adverse outcomes in LF patients[36]. Further studies on liver transplantation indicated that donor diabetes mellitus is associated with inferior outcomes following transplantation[37]. Therefore, it can be concluded that both cigarette smoke exposure and diabetes may diminish the protective effect of ALSS treatment in prolonging survival among patients with LF.

Notably, abnormal procalcitonin levels were identified as significant risk factors for mortality in patients with LF. Serum procalcitonin levels serve as reliable prognostic indicators for 30-day mortality and should be incorporated into clinical practice to stratify risk and facilitate early, effective treatment in acute-on-chronic LF patients[38]. LF patients exhibit elevated serum procalcitonin levels, irrespective of bacterial infections, with higher levels correlating with poorer prognoses[39]. These findings reinforce our conclusions from an alternative perspective. While procalcitonin was recognized as an early diagnostic marker for bacterial infection, it also serves as a precise indicator of mortality risk. You et al. indicate that procalcitonin is a moderately accurate diagnostic marker for post-operative infections in adult liver transplant recipients. A recent study conducted among Indian patients with ALF suggested that in those who underwent PE treatment, procalcitonin (HR=1.18, 95% CI=1.07-1.30) was identified as an independent predictor of mortality[40]. Furthermore, its diagnostic performance can be enhanced when combined with other inflammatory biomarkers [41]. Fan et al. reported that the neutrophil-lymphocyte ratio could predict short-term mortality in acute-on-chronic LF patients undergoing treatment with ALSS[42]. Thus, procalcitonin may represent a valuable prognostic biomarker for individuals suffering from LF.

This study has several limitations. Firstly, as a retrospective study, the authenticity of the information is challenging to ensure, and

Table 4

Univariate and multivariate analyses demonstrating the association between demographic factors, clinical characteristics, and mortality in patients with LF.

Characteristics	Univariate HR(95%CI)	p-value	Multivariate HR(95%CI)	p-value
Sex				
Female vs. Male	1.313(0.948-1.817)	0.101	1.422(0.939-2.153)	0.096
Age group (years)				
≥50 vs. <50	1.311(0.946-1.815)	0.103	1.267(0.902-1.778)	0.172
Hospital stays				
Long vs. short	1.139(0.754-1.718)	0.536		
BMI				
Non-obesity vs. Obesity	0.433(0.228-0.823)	0.011		
Smoke status				
Yes vs. No	0.830(0.579-1.188)	0.309	0.843(0.533-1.332)	0.464
Drink status				
Yes vs. No	1.008(0.725-1.400)	0.964	1.347(0.875-2.074)	0.177
Hypertension				
Yes vs. No	1.161(0.765-1.761)	0.484	1.067(0.688-1.655)	0.773
Diabetes				
Yes vs. No	1.471(0.909-2.383)	0.116		
Virus-induced LF				
Yes vs. No	0.964(0.696-1.335)	0.825	1.065(0.752-1.508)	0.724
ALSS				
Yes vs. No	0.504(0.345-0.735)	<0.001	0.533(0.374-0.760)	0.001
Nosocomial infection				
Yes vs. No	0.904(0.653-1.251)	0.541	1.089(0.775-1.530)	0.645
C-reactive protein				
Normal vs. Abnormal	1.345(0.809-2.237)	0.253		
Procalcitonin				
Normal vs. Abnormal	18.61(4.126-84.00)	<0.001	17.35(5.201-83.55)	0.001
White cell count				
Normal vs. Abnormal	0.610(0.343-1.084)	0.092	0.833(0.454-1.528)	0.566
Neutrophils				
Normal vs. Abnormal	1.629(0.972-2.729)	0.064		
Monocytes				
Normal vs. Abnormal	0.909(0.501-1.651)	0.755	0.902(0.439-1.855)	0.799
Lymphocytes				
Normal vs. Abnormal	1.619(0.794-3.300)	0.185		
Hemoglobin				
Normal vs. Abnormal	1.076(0.667-1.735)	0.765	1.820(0.909-3.644)	0.901
Platelet				
Normal vs. Abnormal	1.144(0.665-1.965)	0.627		
International normalized ratio (INR)				
Normal vs. Abnormal	2.933(0.311-9.373)	0.331	2.073(0.266-4.032)	0.114
Prothrombin activity				
Normal vs. Abnormal	1.380(0.933-2.041)	0.160		
Prothrombin time				
Normal vs. Abnormal	1.276(0.911-1.787)	0.156		
Cholinesterase				
Normal vs. Abnormal	1.669(0.827-3.368)	0.153		
Total bilirubin				
Normal vs. Abnormal	0.755(0.493-1.154)	0.194		
Aspartate aminotransferase				
Normal vs. Abnormal	3.530(1.275-9.776)	0.015		
Alanine aminotransferase				
Normal vs. Abnormal	0.951(0.617-1.467)	0.821		
Albumin				
Normal vs. Abnormal	1.179(0.748-1.858)	0.479	1.189(0.714-1.980)	0.505
Creatinine				
Normal vs. Abnormal	0.609(0.373-1.794)	0.087		
Potassium				
Normal vs. Abnormal	1.242(0.887-1.740)	0.208	1.614(0.830-3.138)	0.158
Sodium				
Normal vs. Abnormal	1.197(0.760-1.885)	0.437		
Blood ammonia				
Normal vs. Abnormal	1.359(0.918-2.012)	0.125		

LF, liver failure; HR, hazard ratio; CI: confidential interval; BMI, body mass index; ALSS, Artificial Liver Support Systems.

recall bias is difficult to eliminate. Additionally, due to the opportunistic nature of its diagnostic and therapeutic approach, the study could only include patients who sought medical care at healthcare institutions. This limitation may introduce potential selection bias among participants and result in uneven baseline characteristics. Then, We are unable to fully capture certain clinical parameters in

the historical medical records due to the retrospective design of this study. Consequently, important indicators of patient status, such as coma grade, MELD score, and Child-Pugh score, cannot be assessed. Nevertheless, we can indirectly evaluate the severity of the patient's condition. For example, INR, bilirubin levels, and creatinine are critical components used in calculating the MELD score. Furthermore,




Fig. 1. Kaplan-Meier curves illustrating the overall survival of patients with LF, categorized according to the treatment modalities.

Table 5

Subgroup and interaction effect analyses demonstrating association between ALSS and mortality in patients with LF.

Demographic factors	SMC	ALSS	p-value	Interaction effect	p-value
Sex					
Male	Reference	0.456(0.286-0.727)	0.001	2.084(0.867-5.011)	0.101
Female	Reference	0.711(0.413-0.988)	0.018		
Age group					
≥50 y	Reference	0.605(0.376-0.974)	0.038	1.446(0.714-2.927)	0.305
<50 y	Reference	0.509(0.297-0.872)	0.014		
BMI					
Non-obesity	Reference	0.378(0.259-0.553)	<0.001	3.359(0.350-8.897)	0.514
Obesity	Reference	0.695(0.120-0.948)	0.003		
Smoke status					
Yes	Reference	0.604(0.303-1.203)	0.151	1.005(0.391-2.582)	0.993
No	Reference	0.514(0.340-0.776)	0.002		
Drink status					
Yes	Reference	0.520(0.290-0.933)	0.028	0.768(0.330-1.790)	0.541
No	Reference	0.546(0.349-0.853)	0.008		
Hypertension					
Yes	Reference	0.554(0.248-0.740)	0.011	0.737(0.297-1.826)	0.510
No	Reference	0.527(0.355-0.783)	0.002		
Diabetes					
Yes	Reference	0.891(0.341-2.332)	0.815	1.389(0.496-3.885)	0.531
No	Reference	0.509(0.348-0.744)	<0.001		
Virus-induced LF					
Yes	Reference	0.422(0.255-0.696)	0.001	0.681(0.328-1.414)	0.303
No	Reference	0.677(0.402-0.942)	0.044		
Nosocomial infection					
Yes	Reference	0.699(0.378-0.990)	0.006	2.215(0.573-4.572)	0.103
No	Reference	0.303(0.181-0.506)	<0.001		

LF, liver failure; SMC, standard medical care; BMI, body mass index; ALSS, Artificial Liver Support Systems.

relevant parameters including bilirubin, albumin, prothrombin time, and blood ammonia levels are available in our dataset and can provide insights into the status of hepatic encephalopathy to some extent. Lastly, the limited number of patients from a single center may also impact the findings of this research.

5. Conclusions

In conclusion, ALSS is not an independent risk factor for nosocomial infections and can effectively prolong the lifespan of LF patients without liver transplantation. The application of ALSS provides a valuable therapeutic option, offering hope and improved prognosis for individuals with LF, offering them a greater chance of survival.

Author contributions

Conceptualization: Yuan Li, Xiaoting Wang and Yan Wang; Data curation: Yuan Li, Xiaoting Wang, Junkai Fan, Jiale Xie and Chunrong Ping; Formal analysis: Yuan Li, Xiaoting Wang, Junkai Fan and Huimin Liu; Software: Yuan Li and Xiaoting Wang; Visualization: Yuan Li and Xiaoting Wang; Writing – original draft: Yuan Li, Xiaoting Wang and Yan Wang; Writing – review & editing: Yuan Li, Xiaoting Wang, Junkai Fan, Jiale Xie, Huimin Liu, Chunrong Ping, Zhijie Feng and Yan Wang. All authors reviewed and approved the final version of the manuscript.

Declaration of generative AI and AI-assisted technologies in the writing process

No AI or AI-assisted technologies were used during the preparation of this work.

Funding

This work was supported by Key Science and Technology Research Program of Health Commission of Hebei Province (20200930 to Yan Wang).

Declaration of interests

None.

References

- [1] Hanish SI, Stein DM, Scales JR, Essien EO, Thurman P, Hutson WR, et al. Molecular adsorbent recirculating system effectively replaces hepatic function in severe acute liver failure. *Ann Surg* 2017 Oct;266(4):677–84. <https://doi.org/10.1097/SLA.0000000000002361>.
- [2] Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure. *Curr Opin Crit Care* 2019 Apr;25(2):187–91. <https://doi.org/10.1097/MCC.0000000000000584>.
- [3] Mezzano G, Juanola A, Cardenas A, Mezey E, Hamilton JP, Pose E, et al. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. *Gut* 2022 Jan;71(1):148–55. <https://doi.org/10.1136/gutjnl-2020-322161>.
- [4] Martínez-Martínez LM, Rosales-Sotomayor G, Jasso-Baltazar EA, Torres-Díaz JA, Aguirre-Villarreal D, Hurtado-Díaz de León I, et al. Acute liver failure: management update and prognosis. *Rev Gastroenterol Mex (Engl Ed)* 2024 Jul-Sep;89(3):404–17. <https://doi.org/10.1016/j.rgmxen.2024.05.002>.
- [5] Sharma P, Schaubel DE, Gong Q, Guidinger M, Merion RM. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. *Hepatology* 2012 Jan;55(1):192–8. <https://doi.org/10.1002/hep.24632>.
- [6] Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019;70:151–71. <https://doi.org/10.1016/j.jhep.2018.09.014>.
- [7] Essing T, Bock H, Wieland B, Fluegen G, Bednarsch J, Bode JG, et al. Clinical determinants of hospital mortality in liver failure: a comprehensive analysis of 62,717 patients. *Z Gastroenterol* 2023 Nov;61(11):1472–83. <https://doi.org/10.1055/a-2016-9061>.
- [8] Chen Y, Han T, Duan Z. Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Clinical application of artificial liver and blood purification: expert consensus recommendations. *Hepatology Int* 2022;38:767–75. <https://doi.org/10.1007/s12072-022-10430-8>.
- [9] Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. *Nat Rev Gastroenterol Hepatol* 2016;13:131–49. <https://doi.org/10.1038/nrgastro.2015.219>.
- [10] Nicolas CT, Wang Y, Nyberg SL. Cell therapy in chronic liver disease. *Curr Opin Gastroenterol* 2016;32:189–94. <https://doi.org/10.1097/MOG.0000000000000262>.
- [11] Saliba F, Bañares R, Larsen FS, Wilmer A, Parés A, Mitzner S, et al. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. *Intens Care Med* 2022 Oct;48(10):1352–67. <https://doi.org/10.1007/s00134-022-06802-1>.
- [12] Li D, Wang X, Zhou J, Duan Z, Yang R, Liu Y, et al. Analysis of efficacy and safety of small-volume-plasma artificial liver model in the treatment of acute-on-chronic liver failure. *Physiol Res* 2023 Dec 31;72(6):767–82. <https://doi.org/10.33549/physiores.935158>.
- [13] Song Z, Xie Q, Zhou Y, Song S, Gao Z, Lan Y, et al. Effect of artificial liver support systems on gut microbiota in patients with HBV-related acute-on-chronic liver failure. *Pathogens* 2023 Aug 28;12(9):1094. <https://doi.org/10.3390/pathogens12091094>.
- [14] Zhang X, Qin D, Liu G, Li F, Peng J, Xiang Y, et al. Risk factors of nosocomial infection in patients underwent artificial liver support system: a retrospective case-control study. *Eur J Gastroenterol Hepatol* 2023 May;35(5):604–8. <https://doi.org/10.1097/MEG.0000000000002547>.
- [15] Lu S, Liu J, Ding Y, Wang D, Zhao H, Zhou H, et al. Predicting bloodstream infection in high-risk groups of liver failure patients with artificial liver support system. *Altern Ther Health Med* 2024 Jun 28;AT10348.
- [16] Misra AC, Eckhoff D. The development of artificial livers. *Curr Opin Organ Transplant* 2021 Oct 1;26(5):468–73. <https://doi.org/10.1097/MOT.0000000000000907>.
- [17] Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, et al. Nosocomial infections are frequent and negatively impact outcomes in hospitalized patients with cirrhosis. *Am J Gastroenterol* 2019 Jul;114(7):1091–100. <https://doi.org/10.14309/ajg.0000000000000280>.
- [18] Donnelly MC, Hayes PC, Simpson KJ. Role of inflammation and infection in the pathogenesis of human acute liver failure: clinical implications for monitoring and therapy. *World J Gastroenterol* 2016 Jul 14;22(26):5958–70. <https://doi.org/10.3748/wjg.v22.i26.5958>.
- [19] Alshamsi F, Alshammari K, Belley-Cote E, Dionne J, Albrahim T, Albudoor B. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. *Intensive Care Med* 2020 Jan;46(1):1–16. <https://doi.org/10.1007/s00134-019-05783-y>.
- [20] van Leeuwen DJ, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Colombari R, et al. Acute-on-chronic liver failure 2018: a need for (urgent) liver biopsy? *Expert Rev Gastroenterol Hepatol* 2018 Jun;12(6):565–73. <https://doi.org/10.1080/17474124.2018.1481388>.
- [21] Wong F, Piano S, Singh V, Bartoletti M, Maiwall R, Alessandria C, et al. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. *J Hepatol* 2021 Feb;74(2):330–9. <https://doi.org/10.1016/j.jhep.2020.07.046>.
- [22] Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. *Liver Int* 2009;29:1396–402. <https://doi.org/10.1111/j.1478-3231.2009.02077.x>.
- [23] Lopes-Secundo TM, Sevã-Pereira T, Correa BR, Silva NCM, Imbrizi MR, Cunha-Silva M, et al. Serum sodium, model for end-stage liver disease, and a recent invasive procedure are risk factors for severe acute-on-chronic liver failure and death in cirrhotic patients hospitalized with bacterial infection. *Eur J Gastroenterol Hepatol* 2018;30(9):1055–9. <https://doi.org/10.1097/MEG.0000000000001184>.
- [24] Lin LN, Zhu Y, Che FB, Gu JL, Chen JH. Invasive fungal infections secondary to acute-on-chronic liver failure: a retrospective study. *Mycoses* 2013;56:429–33. <https://doi.org/10.1111/myc.12044>.
- [25] Lugg ST, Scott A, Parekh D, Naidu B, Thickett DR. Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease. *Thorax* 2022 Jan;77(1):94–101. <https://doi.org/10.1136/thoraxjnl-2020-216296>.
- [26] Kassicheh CS, Kassicheh AJ, Rumalla K, Courville EN, Cole KL, Kazim SF, et al. Hospital-acquired infection following spinal tumor surgery: A frailty-driven pre-operative risk model. *Clin Neurol Neurosurg* 2023 Feb;225:107591. <https://doi.org/10.1016/j.clineuro.2023.107591>.
- [27] Pavlovic D, Miloradovic D, Stojanovic MD, Harrell CR, Polosa R, Rust S, et al. Cigarette smoke attenuates mesenchymal stem cell-based suppression of immune cell-driven acute liver failure. *Toxicol Lett* 2023 Aug 15;385:12–20. <https://doi.org/10.1016/j.toxlet.2023.08.006>.
- [28] Delgado-Rodríguez M, Mariscal-Ortiz M, Gómez-Ortega A, Martínez-Gallego G, Palma-Pérez S, Sillero-Arenas M, et al. Alcohol consumption and the risk of nosocomial infection in general surgery. *Br J Surg* 2003 Oct;90(10):1287–93. <https://doi.org/10.1002/bjs.4186>.
- [29] Puri P, Lee WM, Fontana RJ, Kim NK, Durkalski V, McGuire BM, et al. Alcohol consumption is associated with the severity and outcome of acute liver injury/failure. *Liver Int* 2020 Feb;40(2):360–7. <https://doi.org/10.1111/liv.14327>.
- [30] Duseja A, De A, Taneja S, Choudhury AK, Devarbhavi H, Hu J, et al. Impact of metabolic risk factors on the severity and outcome of patients with alcohol-associated acute-on-chronic liver failure. *Liver Int* 2021 Jan;41(1):150–7. <https://doi.org/10.1111/liv.14671>.
- [31] Li H, Chen HS, Nyberg SL. Extracorporeal liver support and liver transplant for patients with acute-on-chronic liver failure. *Semin Liver Dis* 2016 May;36(2):153–60. <https://doi.org/10.1055/s-0036-1583197>.

- [32] Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. N Engl J Med 2008 Sep;359(10):1018–26. <https://doi.org/10.1056/NEJMoa0801209>.
- [33] Cisneros-Garza LE, Muñoz-Ramírez Mdel R, Muñoz-Espinoza LE, Ruiz Velasco JA, Moreno-Alcántar R, Marín-López E, et al. The molecular adsorbent recirculating system as a liver support system: summary of Mexican experience. Ann Hepatol 2014 Mar-Apr;13(2):240–7.
- [34] Onor IO, Stirling DL, Williams SR, Bediako D, Borghol A, Harris MB, et al. Clinical effects of cigarette smoking: epidemiologic impact and review of pharmacotherapy options. Int J Environ Res Public Health 2017 Sep;14(10):1147. <https://doi.org/10.3390/ijerph14101147>.
- [35] Milosavljevic N, Gazdic M, Simovic Markovic B, Arsenijevic A, Nurkovic J, Dolicanin Z, et al. Mesenchymal stem cells attenuate acute liver injury by altering ratio between interleukin 17 producing and regulatory natural killer T cells. Liver Transpl 2017 Aug;23(8):1040–50. <https://doi.org/10.1002/lt.24784>.
- [36] Kumar A, Arora A, Choudhury A, Arora V, Rela M, Jothimani DK, et al. Impact of diabetes, drug-induced liver injury, and sepsis on outcomes in metabolic dysfunction associated fatty liver disease-related acute-on-chronic liver failure. Am J Gastroenterol 2024 Jul 17. <https://doi.org/10.14309/ajg.0000000000002951>.
- [37] Zhou J, Ye D, Zhang S, Chen Z, Xu F, Ren S, et al. Impact of donor diabetes mellitus status on liver transplant outcomes in patients with acute-on-chronic liver failure. Expert Rev Gastroenterol Hepatol 2023 May;17(5):509–17. <https://doi.org/10.1080/17474124.2023.2197210>.
- [38] Igna R, Muzica C, Zenovia S, Minea H, Girleanu I, Huiban L, et al. The value of pre-sepsin and procalcitonin as prognostic factors for mortality in patients with alcoholic liver cirrhosis and acute on chronic liver failure. Arch Clin Cases 2024 Jul 16;11(2):61–8. <https://doi.org/10.22551/2024.43.1102.10290>.
- [39] Sato S, Sato S, Tsuzura H, Ikeda Y, Hayashida S, Takahashi S, et al. Elevated serum procalcitonin levels and their association with the prognosis of patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020 Sep;32(9):1222–8. <https://doi.org/10.1097/MEG.0000000000001644>.
- [40] Roy A, Kumar K, Premkumar M, et al. Current status of etiology and outcomes of acute liver failure in India-A multicentre study from tertiary centres. Ind J Gastroenterol 2025;44(1):47–56. <https://doi.org/10.1007/s12664-024-01634-x>.
- [41] You P, Gao RY, Han YZ, Zhang XK, Li WX, Huang LF. Diagnostic accuracy of procalcitonin for infection after adult liver transplantation: A meta-analysis and systematic review. Surg Infect (Larchmt) 2023 Nov;24(9):763–72. <https://doi.org/10.1089/sur.2023.206>.
- [42] Fan Z, EnQiang C, Yao DL, LiBo Y, Hong L, Lang B, et al. Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system. PLoS One 2017 Apr 20;12(4):e0175332. <https://doi.org/10.1371/journal.pone.0175332>.